Genes At Work Since its founding in 1976, Genentech has fostered a culture of casual intensity that has consistently led to success. In 1996, among the three regulatory clearances achieved by its workforce was a new indication for ActivaseÆ (Alteplase, recombinant) for the treatment of acute ischemic stroke within the first three hours of symptom onset. As a result, the medical community for the first time recognizes ischemic stroke as a treatable medical emergency.

Statement by Genentech Cofounder Herber W. Boyer
"Genentech's unique culture is no accident. At the very beginning we planned to bring the best characteristics of an academic environment to the Genentech corporate culture. We hired the most competent, enthusiastic people we could find, provided a stimulating, challenging, yet supportive environment, and encouraged publication, peer interaction, and open communication.

That tradition of looking for the best people, the right people, and encouraging their creativity has continued through the years and has been what makes Genentech 'work'. I take great pride in their dedication and enthusiasm and their significant contribution to science and human health." - Herbert W. Boyer, Ph.D. Genentech Cofounder Table of Contents
Financial Highlights (PDF/33K) Letter to Stockholders (PDF/38K) Business Highlights (PDF/18K) Marketed Products (PDF/451K) Research and Development (PDF/730K)		Business Development (PDF/151K) Manufacturing (PDF/57K) Financials (PDF/145K) Board of Directors, Staff Scientists and Officers (PDF/67K)

To open PDF documents, please download the latest version of Adobe Acrobat Reader, a free download.